Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.

Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.

Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.

Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.

Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.

Finasteride helps reduce pain and inflammation in animals.

New chemical compounds were made that effectively block an enzyme linked to prostate growth.

SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.

PNU157706 reduced rat sperm movement and fertility without affecting offspring health.

Finasteride and dutasteride can harm male reproductive health, affecting sperm and causing sexual dysfunction.

Finasteride may reduce prostate tumor cell invasion and spread.

Finasteride may be linked to Peyronie’s disease, but more research is needed.

Finasteride may increase the risk of suicidality and depression, especially in younger people.

Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.

The effectiveness of platelet-rich plasma for erectile dysfunction is still unclear.

Drugs for hormone-related conditions might help treat mental disorders but could have serious side effects.

Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.

New compounds called benzoquinolinones may treat conditions linked to excess DHT.

Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.

New pregnane derivatives are effective at inhibiting an enzyme linked to hair loss and reducing oil gland activity.

Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.

Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.

Finasteride may help reduce inappropriate sexual behaviors in dementia patients with prostate issues.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.

5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Finasteride increases P-glycoprotein activity in the liver and kidney.

Finasteride may cause changes in dopamine-related genes, possibly leading to post-finasteride syndrome.